Ciliary Body Melanoma Staging
Ciliary body melanoma is staged using the AJCC 8th edition TNM staging system specifically designed for uveal melanomas, which differs fundamentally from cutaneous melanoma staging and is based on tumor size, extent of intraocular involvement, and extraocular extension rather than Breslow thickness or ulceration.
Critical Distinction: Uveal vs. Cutaneous Melanoma
The evidence provided primarily addresses cutaneous melanoma staging 1, 2, 3, 4, which is not applicable to ciliary body melanoma. Ciliary body melanoma is a uveal (intraocular) melanoma, requiring a completely different staging approach. The cutaneous melanoma staging tables and criteria (Breslow thickness, ulceration, Clark levels) shown in the guidelines 1 do not apply to uveal melanomas.
AJCC 8th Edition TNM for Uveal Melanoma
T Category (Primary Tumor)
The T staging for ciliary body melanoma is based on:
- Tumor size (measured in largest basal diameter and thickness)
- Anatomic location within the uvea (iris, ciliary body, choroid)
- Extent of local invasion (extraocular extension)
Key T-stage criteria for ciliary body involvement:
- Tumors involving the ciliary body are typically classified as T2-T4 depending on size
- Extraocular extension significantly upstages the tumor
- Involvement of adjacent structures (sclera, orbit) affects T classification
N Category (Regional Lymph Nodes)
- N0: No regional lymph node metastasis
- N1: Regional lymph node metastasis
Important caveat: Regional lymph node metastasis from uveal melanoma is extremely rare (unlike cutaneous melanoma), occurring in <1% of cases. Sentinel lymph node biopsy is not indicated for uveal melanomas.
M Category (Distant Metastasis)
- M0: No distant metastasis
- M1a: Metastasis to one distant site
- M1b: Metastasis to two or more distant sites
- M1c: Metastasis with elevated LDH
Critical point: Uveal melanomas have a distinct metastatic pattern, predominantly spreading hematogenously to the liver (>90% of metastases), unlike cutaneous melanoma which commonly involves lymph nodes first.
Volume-Based Staging Validation
Recent research 5 demonstrates that a volume-based staging system using estimated tumor volume from routine clinical measurements (basal diameter and thickness) provides superior prognostic discrimination compared to the AJCC 8th edition for choroidal and ciliary body melanomas. This study showed:
- Net reclassification improvement of 23%
- 15-year metastatic death rates ranging from 7% to 76% (wider absolute range than AJCC)
- Better hazard ratio discrimination (peak HR of 24 vs. 13 for AJCC)
However, the AJCC 8th edition remains the standard for clinical staging and reporting until this volume-based system is formally adopted.
Staging Workup Requirements
For ciliary body melanoma staging:
- Ophthalmologic examination with detailed fundoscopy and ultrasound biomicroscopy
- Ocular ultrasound to measure tumor dimensions (basal diameter and thickness)
- Systemic imaging for metastatic disease:
- Liver imaging (MRI or CT) - mandatory given liver tropism
- Chest imaging
- Consider PET/CT for higher-stage disease
Common Pitfalls to Avoid
- Do not apply cutaneous melanoma staging criteria (Breslow thickness, ulceration, sentinel node biopsy) to ciliary body melanoma
- Do not perform sentinel lymph node biopsy - it has no role in uveal melanoma staging
- Do not use the staging tables shown in the cutaneous melanoma guidelines 1 for ciliary body tumors
- Always obtain accurate tumor measurements via ultrasound - clinical estimation is insufficient
- Prioritize liver surveillance over lymph node assessment in follow-up
The mucosal melanoma staging system 6 is also distinct and applies to head and neck mucosal sites, not intraocular melanomas.